904 related articles for article (PubMed ID: 27394404)
21. Antifungal prophylaxis with micafungin in patients treated for childhood cancer.
Kusuki S; Hashii Y; Yoshida H; Takizawa S; Sato E; Tokimasa S; Ohta H; Ozono K
Pediatr Blood Cancer; 2009 Oct; 53(4):605-9. PubMed ID: 19533659
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of a primary antifungal prophylaxis protocol for preventing invasive mold infections after allogeneic hematopoietic stem cell transplantation.
Herity LB; Cruz OA; Aziz MT
J Oncol Pharm Pract; 2022 Jun; 28(4):794-804. PubMed ID: 33906508
[TBL] [Abstract][Full Text] [Related]
23. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients.
Oren I; Rowe JM; Sprecher H; Tamir A; Benyamini N; Akria L; Gorelik A; Dally N; Zuckerman T; Haddad N; Fineman R; Dann EJ
Bone Marrow Transplant; 2006 Jul; 38(2):127-34. PubMed ID: 16751782
[TBL] [Abstract][Full Text] [Related]
24. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
[TBL] [Abstract][Full Text] [Related]
25. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of micafungin for the prophylaxis of invasive fungal infection during neutropenia in children and adolescents undergoing allogeneic hematopoietic SCT.
Park HJ; Park M; Han M; Nam BH; Koh KN; Im HJ; Lee JW; Chung NG; Cho B; Kim HK; Yoo KH; Koo HH; Kang HJ; Shin HY; Ahn HS; Lim YT; Kook H; Lyu CJ; Hah JO; Park JE; Lim YJ; Seo JJ
Bone Marrow Transplant; 2014 Sep; 49(9):1212-6. PubMed ID: 25000455
[TBL] [Abstract][Full Text] [Related]
27. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
[TBL] [Abstract][Full Text] [Related]
28. A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis.
Biehl LM; Vehreschild JJ; Liss B; Franke B; Markiefka B; Persigehl T; Bücker V; Wisplinghoff H; Scheid C; Cornely OA; Vehreschild MJ
J Antimicrob Chemother; 2016 Sep; 71(9):2634-41. PubMed ID: 27317443
[TBL] [Abstract][Full Text] [Related]
29. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
[TBL] [Abstract][Full Text] [Related]
30. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.
Strasfeld L; Weinstock DM
Expert Rev Anti Infect Ther; 2006 Jun; 4(3):457-68. PubMed ID: 16771622
[TBL] [Abstract][Full Text] [Related]
31. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
32. Clinical and pharmacoeconomic evaluation of antifungal prophylaxis with continuous micafungin in patients undergoing allogeneic stem cell transplantation: A six-year cohort analysis.
Wingen-Heimann SM; Cornely OA; Vehreschild MJGT; Wisplinghoff H; Franke B; Schons M; von Bergwelt-Baildon M; Scheid C; Vehreschild JJ
Mycoses; 2021 Apr; 64(4):437-444. PubMed ID: 33354800
[TBL] [Abstract][Full Text] [Related]
33. Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation.
Hashino S; Morita L; Takahata M; Onozawa M; Nakagawa M; Kawamura T; Fujisawa F; Kahata K; Izumiyama K; Yonezumi M; Chiba K; Kondo T; Asaka M
Int J Hematol; 2008 Jan; 87(1):91-7. PubMed ID: 18224421
[TBL] [Abstract][Full Text] [Related]
34. Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients.
Liu F; Wu T; Wang JB; Cao XY; Yin YM; Zhao YL; Lu DP
Transpl Infect Dis; 2013 Jun; 15(3):243-50. PubMed ID: 23496156
[TBL] [Abstract][Full Text] [Related]
35. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.
Kontoyiannis DP; Marr KA; Park BJ; Alexander BD; Anaissie EJ; Walsh TJ; Ito J; Andes DR; Baddley JW; Brown JM; Brumble LM; Freifeld AG; Hadley S; Herwaldt LA; Kauffman CA; Knapp K; Lyon GM; Morrison VA; Papanicolaou G; Patterson TF; Perl TM; Schuster MG; Walker R; Wannemuehler KA; Wingard JR; Chiller TM; Pappas PG
Clin Infect Dis; 2010 Apr; 50(8):1091-100. PubMed ID: 20218877
[TBL] [Abstract][Full Text] [Related]
36. An open-label trial of the prophylactic administration of voriconazole in patients who undergo allogeneic hematopoietic stem cell transplantation: study protocol.
Kunitomi A; Hasegawa Y; Hashimoto H; Saito AM; Iida H
Nagoya J Med Sci; 2018 Nov; 80(4):591-595. PubMed ID: 30587873
[TBL] [Abstract][Full Text] [Related]
37. Clinical and Microbiological Characteristics of Breakthrough Candidemia in Allogeneic Hematopoietic Stem Cell Transplant Recipients in a Japanese Hospital.
Kimura M; Araoka H; Yamamoto H; Asano-Mori Y; Nakamura S; Yamagoe S; Ohno H; Miyazaki Y; Abe M; Yuasa M; Kaji D; Kageyama K; Nishida A; Ishiwata K; Takagi S; Yamamoto G; Uchida N; Izutsu K; Wake A; Taniguchi S; Yoneyama A
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115352
[TBL] [Abstract][Full Text] [Related]
38. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
Winston DJ; Maziarz RT; Chandrasekar PH; Lazarus HM; Goldman M; Blumer JL; Leitz GJ; Territo MC
Ann Intern Med; 2003 May; 138(9):705-13. PubMed ID: 12729424
[TBL] [Abstract][Full Text] [Related]
39. Antifungal prophylaxis in adult hematopoietic stem cell transplant recipients.
Tamura K; Drew R
Drugs Today (Barc); 2008 Jul; 44(7):515-30. PubMed ID: 18806902
[TBL] [Abstract][Full Text] [Related]
40. Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens.
Corzo-León DE; Satlin MJ; Soave R; Shore TB; Schuetz AN; Jacobs SE; Walsh TJ
Mycoses; 2015 Jun; 58(6):325-36. PubMed ID: 25808822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]